Functional B7.2 and B7-H2 molecules on myeloma cells are associated with a growth advantage

Clinical Cancer Research

Volumn 15, Issue 3, 2009, Pages 770-777

  Yamashita, Taishi ^a,c   Tamura, Hideto ^a,b   Satoh, Chikako ^a,b   Shinya, Eiji ^b   Takahashi, Hidemi ^b   Chen, Lieping ^d   Kondo, Asaka ^a   Tsuji, Takashi ^c   Dan, Kazuo ^a   Ogata, Kiyoyuki ^a  

^a Division of Hematology   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c TOKYO UNIVERSITY OF SCIENCE   (Japan)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD86 ANTIGEN; INTERLEUKIN 10; LYMPHOCYTE ANTIGEN; PROTEIN B7 H2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANEMIA; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MYELOMA CELL; PLASMA CELL; PRIORITY JOURNAL; PROTEIN INDUCTION; THROMBOCYTOPENIA;

ANTIGEN-PRESENTING CELLS; ANTIGENS, CD; ANTIGENS, CD86; BONE MARROW CELLS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MODELS, BIOLOGICAL; MULTIPLE MYELOMA;

EID: 61349148810     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0501     Document Type: Article

References (43)

1. Massaia M, Dianzani U, Bianchi A, Camponi A, Boccadoro M, Pileri A. Defective generation of alloreactive cytotoxic T lymphocytes (CTL) in human monoclonal gammopathies. Clin Exp Immunol 1988;73:214-8.
2. Cook G, Campbell JD, Carr CE, Boyd KS, Franklin IM. Transforming growth factor β from multiple myeloma cells inhibits proliferation and IL-2 responsiveness inT lymphocytes. J Leukoc Biol 1999;66:981-8.
3. Campbell JD, Cook G, Robertson SE, et al. Suppression of IL-2-inducedTcell proliferation and phosphorylation of STAT3 and STAT5 by tumor-derived TGF β is reversed by IL-15. J Immunol 2001;167:553-61.
4. Hideshima T, Podar K, Chauhan D, Anderson KC. Cytokines and signal transduction. Best Pract Res Clin Haematol 2005;18:509-24.
5. Yasui H, HideshimaT, Richardson PG, Anderson KC. Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. BrJ Haematol 2006;132:385-97.
6. Borset M,Waage A, Brekke OL, Helseth E. TNF and IL-6 are potent growth factors for OH-2, a novel human myeloma cell line. Eur J Haematol 1994;53:31-7.
7. Filella X, Blade J, Guillermo AL, Molina R, Rozman C, Ballesta AM. Cytokines (IL-6,TNF-α,IL-1 α)and soluble interleukin-2 receptor as serum tumor markers in multiplemyeloma. Cancer Detect Prev 1996;20:52-6.
8. Lu ZY,Zhang XG, Rodriguez C, et al.Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells. Blood 1995;85:2521-7.
9. Otsuki T, Yata K, Sakaguchi H, et al. IL-10 in myeloma cells. Leuk Lymphoma 2002;43:969-74.
10. + lymphocytes from AIDS patients inhibits T cell cytotoxicity. Eur J Immunol 1991;21:737-41.
11. Caux C, Massacrier C, Vanbervliet B, Barthelemy C, Liu YJ, Banchereau J. Interleukin 10 inhibits T cell alloreaction induced by human dendritic cells. Int Immunol 1994;6:1177-85.
12. de la Barrera S, Aleman M, Musella R, et al. IL-10 down-regulates costimulatory molecules on Mycobacterium tuberculosis -pulsed macrophages and impairs the lytic activity of CD4 and CD8 CTL in tuberculosis patients. Clin Exp Immunol 2004;138:128-38.
13. Chen L, Linsley PS, Hellstrom KE. Costimulation of T cells for tumor immunity. Immunol Today 1993;14:483-6.
14. Chen L, McGowan P, Ashe S, et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 1994;179:523-32.
15. 15. Tamura H, Ogata K, Dong H, Chen L. Immunology of B7-1 and its roles in human diseases. Int J Hematol 2003;78:321-8.
16. Carreno BM, Carter LL, Collins M. Therapeutic opportunities in the B7/CD28 family of ligands and receptors. Curr Opin Pharmacol 2005;5:424-30.
17. Swallow MM, Wallin JJ, Sha WC. B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNFα. Immunity 1999;11:423-32.
18. Hutloff A, Dittrich AM, Beier KC, et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999;397:263-6.
19. Wang S, Zhu G, Chapoval AI, et al. Costimulation of T cells by B7-2, a B7-like molecule that binds ICOS. Blood 2000;96:2808-13.
20. Okamoto N, Tezuka K, Kato M, Abe R, Tsuji T. PI3-kinase and MAP-kinase signaling cascades in AILIM/ICOS- and CD28-costimulated T-cells have distinct functions between cell proliferation and IL-10 production. Biochem Biophys Res Commun 2003;310:691-702.
21. Tamura H, Dan K, Tamada K, et al. Expression of functional B7-2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia. Clin Cancer Res 2005;11:5708-17.
22. Pope B, Brown RD, Gibson J, Yuen E, Joshua D. B7-2-positive myeloma: incidence, clinical characteristics, prognostic significance, and implications for tumor immunotherapy. Blood 2000;96:1274-9.
23. -) in patients with myelodysplastic syndromes. Stem Cells 2005;23:619-30.
24. Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-54.
25. Bataille R, Jégo G, Robillard N, et al. The phenotype of normal, reactive and malignant plasma cells. Identification of ''many and multiple myelomas'' and of new targets for myeloma therapy. Haematologica 2006;91:1234-40.
26. Gimeno MJ, Maneiro E, Rendal E, Ramallal M, Sanjurjo L, Blanco FJ. Cell therapy: a therapeutic alternative to treat focal cartilage lesions. Transplant Proc 2005;37:4080-3.
27. Ogata K, Nakamura K,Yokose N, et al. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood 2002;100:3887-96.
28. Asosingh K,Vankerkhove V, Van Riet I, Van Camp B, Vanderkerken K. Selective in vivo growth of lymphocyte function-associated antigen-1-positive murine myeloma cells. Involvement of function-associated antigen-1-mediated homotypic cell-cell adhesion. Exp Hematol 2003;31:48-55.
29. Schmidmaier R, Morsdorf K, Baumann P, Emmerich B, Meinhardt G. Evidence for cell adhesion-mediated drug resistance of multiple myeloma cells in vivo.Int J Biol Markers 2006;21:218-22.
30. Kuchroo VK, Das MP, Brown JA, et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995;80:707-18.
31. + T cell responses by ICOS/B7h costimulation. J Immunol 2001;167:132-9.
32. Wang G, Zhu L, Hu P, et al. The inhibitory effects of mouse ICOS-Ig gene-modified mouse dendritic cells on T cells. Cell Mol Immunol 2004;1:153-7.
33. Taylor PA, Panoskaltsis-Mortari A, Freeman GJ, et al. Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM). Blood 2005;105:3372-80.
34. Ansari MJ, Fiorina P, Dada S, et al. Role of ICOS pathway in autoimmune and alloimmune responses in NOD mice. Clin Immunol 2008;126:140-7.
35. Cheever MA, Greenberg PD, Fefer A, Gillis S. Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2. J Exp Med 1982;155: 968-80.
36. Tuttle TM, McCrady CW, Inge TH, Salour M, Bear HD. γ-Interferon plays a key role in T-cell-induced tumor regression. Cancer Res 1993;53:833-9.
37. Maeda A, Yamamoto K, Yamashita K, et al. The expression of co-stimulatory molecules and their relationship to the prognosis of human acute myeloid leukaemia: poor prognosis of B7-2-positive leukaemia. Br J Haematol 1998;102:1257-62.
38. Stremmel C, Greenfield EA, Howard E, Freeman GJ, Kuchroo VK. B7-2 expressed on EL4 lymphoma suppresses antitumor immunity by an interleukin 4-dependent mechanism. J Exp Med 1999;189:919-30.
39. Thalmeier K, Meissner P, Reisbach G, et al. Constitutive and modulated cytokine expression in two permanent human bone marrow stromal cell lines. Exp Hematol 1996;24:1-10.
40. Silvestris F, Cafforio P, Calvani N, Dammacco F. Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells. Br J Haematol 2004;126:475-86.
41. Ghebeh H,Tulbah A, Mohammed S, et al. Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells. Int J Cancer 2007;121:751-8.
42. Teo SK. Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS J 2005;7:E14-9.
43. List AF. Lenalidomide-the phoenix rises. N Engl J Med 2007;357:2183-6.